DafinchiAs you may know, we have announced at the end of our clinical program that we have all the clinical data we need to submit, but we do need to gather a little bit more on the CMC side.
LLY2026 Q2Healthcare
1mo
Eli Lilly and Company 2026 Q2: Financial Performance summary
Financial Performance Summary
- Gross margin was 86.3% of revenue in Q2, up ~1.3 percentage points year over year, driven primarily by product mix and improved cost of production.
- Key Products increased by almost $6.8B in Q2, with Oncology, Immunology, and Neuroscience collectively up 121% vs the prior year quarter.
- Marketing, selling & administrative expenses increased 25% as Lilly invested in promotional activities for current and planned product launches.
- Mounjaro + Zepbound combined for $14.9B revenue in Q2, contributing $6.3B of growth vs Q2 2025.
- Non-GAAP EPS was $8.38, including acquired IPR&D charges of $3.03 (vs $6.31 EPS in Q2 2025 including $0.14 acquired IPR&D).
- Non-GAAP performance margin was 54.8% in Q2, up 9 percentage points vs 2025 (driven by revenue growth).
- Q2 2026 revenue grew 48% vs Q2 2025 to $48B+ (implied by 48% growth and guidance context), driven by Zepbound and Mounjaro.
- R&D expenses increased 14%, supported by continued investment in the pipeline with more than 40 active Phase 3 programs.